Aekyung Chemical

At a glance

Aekyung Chemical filed 84 disclosures in the last 12 months, including 21 5% holder, 2 buyback, 2 m&a and 1 issuance. The most recent key filing was on Oct 26.

Revenue for 2025 was ₩1.45T, down 11.6% on 2024. It made an operating loss of ₩10.2B. Debt was 95% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩874B and operating profit of ₩48.7B.

The 2025 annual report lists 716 employees with an average tenure of 7.8 years and average pay of ₩68.8M, #748 of 2,191 listed companies by average pay. Its 8 directors and auditors were paid ₩152M each on average. It paid ₩140 per common share in cash dividends, against ₩281 a year earlier (-50.2%). 에이케이홀딩스 and related parties held 62.23% at year end.

Of 5 recent 5%+ holder reports, 0 raised and 0 cut a stake; the largest stake reported was 62.29% on Oct 20.

From the 2025 annual report

Staff: 716 (607 men, 109 women), of whom 16 on fixed-term contracts. Total pay for the year: ₩50.7B. Directors and auditors: 8, paid ₩1.2B in total.

Dividends (common shares)

Largest shareholder

에이케이홀딩스 holds 60.30%; with 10 related parties the group holds 62.23% of common shares at year end (from 62.20% at the start of the year).

Auditor: 한영회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports